New offering to support individuals and
physicians with accessible and convenient testing options to guide
weight loss management decisions and treatments
BURLINGTON, N.C., March 7,
2024 /PRNewswire/ -- Labcorp (NYSE: LH), a
global leader of innovative and comprehensive laboratory services,
announced today the introduction of its Weight Loss Management
portfolio. The new offering features educational resources and
convenient testing solutions, equipping individuals and their
physicians with baseline and ongoing health indicators to inform
treatment options, including lifestyle modifications, Glucagon-like
peptide-1 (GLP-1) medications or bariatric surgery.
More than 40% of U.S. individuals are considered obese,
according to the Centers for Disease Control and Prevention (CDC).
Excess weight and obesity raise the risk of serious health
conditions, including Type 2 diabetes, stroke and cardiovascular
disease. GLP-1 medications for weight loss and diabetes management
are also dramatically changing the weight management landscape.
Nearly 60% of adults who are trying to lose weight – and even a
quarter of those who aren't currently trying to lose weight – say
they would be interested in trying a weight-loss prescription drug,
according to a recent Kaiser Family Foundation poll.
Labcorp's Weight Loss Management offering features proven
tests from Labcorp's comprehensive menu and helps to simplify the
process for both physicians and individuals by outlining which
tests are typically ordered at different stages of an individual's
weight loss journey.
Labcorp's Weight Management Baseline Test captures more than 20
specific factors across blood sugar levels, cholesterol levels,
thyroid function and metabolic function, which are essential to
understand before starting weight management efforts. Weight loss
medications, in particular, can affect liver and kidney function,
so baseline testing on metabolic function is helpful before
starting a GLP-1 medication. The Weight Management Tracking Test
assesses average blood sugar and lipid levels to monitor metabolic
health as an individual progresses along the weight loss journey.
Labcorp's guideline-driven bariatric surgery portfolio offers pre-
and post-surgery profiles that provide insights for key vitamins
and micronutrients that are recommended to be evaluated for
potential deficiencies before and after surgery.
"The introduction of GLP-1s and other weight loss treatments has
increased interest from individuals and their doctors seeking
solutions for effective weight management. Having a baseline
understanding of an individual's health is helpful when choosing
the most effective and personalized treatment," said Dr.
Brian Caveney, Labcorp's chief
medical and scientific officer. "Our Weight Loss Management
offering simplifies the process of obtaining baseline measurements
and tracking health progress to empower informed conversations
about weight loss between individuals and their doctors."
Labcorp's new offering builds upon the company's leadership in
testing for cardiometabolic conditions and its breadth of
experience in supporting individuals and physicians with weight
management. In addition to its baseline, tracking and bariatric
surgery testing portfolio, the company has contributed to bringing
GLP-1 medications to market through clinical trial support. Labcorp
also invests in innovative start-up entities through the Labcorp
Venture Fund that are developing tools and services to support
weight management to help deliver new and more effective solutions
for individuals and providers.
To learn more about Labcorp's Weight Loss Management portfolio,
visit https://www.labcorp.com/weight-management.
About Labcorp
Labcorp (NYSE: LH) is a global
leader of innovative and comprehensive laboratory services that
helps doctors, hospitals, pharmaceutical companies, researchers and
patients make clear and confident decisions. We provide insights
and advance science to improve health and improve lives through our
unparalleled diagnostics and drug development laboratory
capabilities. The company's more than 67,000 employees serve
clients in over 100 countries, worked on over 84% of the new drugs
approved by the FDA in 2023 and performed more than 600 million
tests for patients around the world. Learn more about us
at www.labcorp.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-weight-loss-management-testing-solutions-302082835.html
SOURCE Labcorp